Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks

In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS). A 39-year-old female patient with CNV secondary to AS had bilateral persistent intrar...

Full description

Saved in:
Bibliographic Details
Published in:Indian journal of ophthalmology 2015-07, Vol.63 (7), p.616-618
Main Authors: Esen, Ebru, Sizmaz, Selçuk, Demircan, Nihal
Format: Article
Language:English
Subjects:
Adult
Aflibercept
angioid streaks
Angioid Streaks - complications
Angioid Streaks - diagnosis
Brief Communication
Choroid - pathology
choroidal neovascularization
Choroidal Neovascularization - diagnosis
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - etiology
Diagnosis
Drug dosages
Drug therapy
Eye diseases
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Macular degeneration
Neovascularization
Patient outcomes
Patients
Receptors, Vascular Endothelial Growth Factor - administration & dosage
Recombinant Fusion Proteins - administration & dosage
Retina - diagnostic imaging
Studies
Tomography, Optical Coherence
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this study, we reported the clinical results of switching from ranibizumab to aflibercept for the treatment of an insufficient responder with choroidal neovascularization (CNV) secondary to angioid streaks (AS). A 39-year-old female patient with CNV secondary to AS had bilateral persistent intraretinal and subretinal fluid on the optical coherence tomography despite prior intravitreal 0.5 mg ranibizumab injections. The therapy was switched to intravitreal injection of aflibercept. The patient received a loading dose of three intravitreal 2 mg aflibercept injections at 4-week intervals for both eyes. Morphological and functional effects were observed as early as 1-week after the first injection. After the third aflibercept injection, her visual acuity improved, intraretinal and subretinal fluid resolved, and central macular thickness reduced in both eyes. This is an early, but encouraging and promising result indicating that aflibercept might be a good alternative management for CNV secondary to AS that is insufficiently responding to prior ranibizumab injections.
ISSN:0301-4738
1998-3689
DOI:10.4103/0301-4738.167121